Pytel Peter
University of Chicago Medical Center, Department of Pathology, MC6101, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S51-60. doi: 10.1586/14737140.7.12s.S51.
The therapy of gliomas is still challenging. This is especially true for pediatric gliomas because response to conventional cytotoxic chemotherapy agents and radiation therapy is currently often poor and because therapy-related morbidity is a significant problem in children. Stratification of tumors according to biologic characteristics and new more targeted therapies therefore hold the promise of better tumor control as well as reduced side effects. Significant progress has been made in recent years in understanding the biology of gliomas. These new insights into the molecular mechanism driving tumor growth uncover new potential molecular targets for future therapies. In addition, they start to uncover biologically defined tumor subtypes that may have to be considered independently in the search for optimal treatment regimens.
胶质瘤的治疗仍然具有挑战性。对于儿童胶质瘤来说尤其如此,因为目前对传统细胞毒性化疗药物和放射治疗的反应往往较差,而且治疗相关的发病率在儿童中是一个重大问题。因此,根据生物学特征对肿瘤进行分层以及采用新的更具针对性的疗法有望更好地控制肿瘤并减少副作用。近年来在理解胶质瘤生物学方面取得了重大进展。这些对驱动肿瘤生长的分子机制的新见解揭示了未来治疗的新潜在分子靶点。此外,它们开始揭示生物学上定义的肿瘤亚型,在寻找最佳治疗方案时可能需要单独考虑这些亚型。